Iroprem (Ferric Carboxymaltose)

Ferric carboxymaltose delivers elemental iron directly into the bloodstream. The iron binds to transferrin, is transported to the bone marrow, and is incorporated into newly formed hemoglobin, thereby bypassing the gastrointestinal tract and rapidly replenishing depleted iron stores.

The dose of Iroprem is individualized by the prescribing clinician based on the patient’s iron deficit, body weight, and clinical condition. The prescriber determines the total amount and infusion rate according to approved guidelines and laboratory monitoring.

Safety of Iroprem during pregnancy or lactation has not been definitively established. It should only be used if the potential benefit to the mother outweighs any possible risk to the fetus or infant, and the decision must be made by a qualified healthcare professional.

To order Iroprem, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India supplies hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details (including cold‑chain logistics if needed) and required import documentation.

The primary alternative to Iroprem is iron sucrose, another intravenous iron. Ferric carboxymaltose (Iroprem) allows larger single‑dose administrations with a shorter infusion time, whereas iron sucrose typically requires multiple smaller doses. Both are effective, but the choice depends on patient tolerance, dosing convenience, and physician preference.

Iroprem must be stored at 2‑8 °C in a refrigerator, protected from light. It should not be frozen or shaken. Before use, inspect the solution for particulate matter and ensure the vial is within the recommended temperature range.

Iroprem is given by intravenous infusion. The recommended infusion rate and total dose are determined by the prescriber, and the product is administered through a suitable IV line under medical supervision, with monitoring for any infusion‑related reactions.

The most serious adverse events associated with Iroprem include anaphylactic reactions, severe hypotension during infusion, and iron overload if cumulative dosing exceeds the patient’s needs. Prompt recognition and management of these events are essential.

Iroprem is contraindicated in patients with known hypersensitivity to ferric carboxymaltose or any of its excipients, those with active severe infections, and individuals with documented iron overload disorders. Caution is also advised for patients with uncontrolled hypertension.